HHS Drug Cost Forum: Merck, Novartis To Represent Industry View
This article was originally published in The Pink Sheet Daily
Executive Summary
The two big pharmas are the only representatives of branded drug manufacturers scheduled to participate in the meeting. GPhA’s Chip Davis is on the agenda to represent the generic drug industry's point of view.
You may also be interested in...
HHS Raises Profile In Drug Costs Discussion
On Nov. 20, HHS will host a day-long forum on pharmaceuticals, including a look at high-cost specialty drugs and innovative purchasing strategies.
FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Khan Says
The agency is also poised to announce another development in its scrutiny of the drug patents listed in the FDA’s Orange Book.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.